plicamycin plicamycin plicamycin (inn, also known as mithramycin; trade name mithracin) is an antineoplastic antibiotic produced by streptomyces plicatus. it is an rna synthesis inhibitor. the manufacturer discontinued production in 2000. several different structures are currently reported in different places all with the same chromomycin core, but with different stereochemistry in the glycoside chain, a 1999 study has re-investigated the compound and proposed a revised structure. plicamycinclinical dataother namesaureolic acid; mithracin; antibiotic la 7017; mithramycin a; mitramycin; plicatomycinahfs/drugs.commicromedex detailed consumer informationroutes ofadministrationintravenousatc codel01dc02 (who) legal statuslegal status us: ℞-only discontinued identifiers iupac name (1s)-5-deoxy-1-c-((2s,3s)-7--3--5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl)-1-o-methyl-d-xylulose cas number18378-89-7 ypubchem cid5284610drugbankdb06810 ychemspider4447655 yuniinij123w41vkeggd00468 nchemblchembl509846 ncomptox dashboard (epa)dtxsid6023492 echa infocard100.162.065 chemical and physical dataformulac52h76o24molar mass1085.156 g·mol−13d model (jsmol)interactive image smiles co(c(=o)(o)(c)o)c1cc2cc3cc(o4c(o5c(o)(o)(c)o5)(o)(c)o4)c(c)c(o)c3c(o)c2c(=o)1o1c(o2c(o3c(c)(o)(o)(c)o3)(o)(c)o2)(o)(c)o1 inchi inchi=1s/c52h76o24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65h,11,13-17h2,1-9h3/t19-,20-,21-,22-,23-,24-,27?,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43+,44-,45-,49+,50+,51-,52+/m1/s1 ykey:cfcuwkmkbjtwlw-gwrqqdndsa-n y ny (what is this?) (verify) uses plicamycin has been used in the treatment of testicular cancer, paget's disease of bone, and, rarely, the management of hypercalcemia. plicamycin has been tested in chronic myeloid leukemia. plicamycin is currently used in multiple areas of research, including cancer cell apoptosis and as a metastasis inhibitor. one elucidated pathway shows it interacts by cross-binding chromatin gc-rich promoter motifs, thereby inhibiting gene transcription.